The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-01. Anything still debated is marked as such rather than presented as settled.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Pre-procedure, every patient used external vacuum expansion of the recipient-site tissues to create a breast tissue matrix to be injected with autologous fat grafts of adipocyte tissue, refined via low G-force centrifugation. Pre- and post-procedure, the breast volumes were measured; the patients underwent pre-procedure and 6-month post-procedure MRI and 3D volumetric imaging examinations. At six months post-procedure, each woman had a significant increase in breast volume, ranging 60–200 percent, per the MRI (n=12) examinations. The size, form, and feel of the breasts was natural; post-procedure MRI examinations revealed no oil cysts or abnormality (neoplasm) in the fat-augmented breasts. Moreover, given the sensitive, biologic nature of breast tissue, periodic MRI and 3-D volumetric imaging examinations are required to monitor the breast-tissue viability and the maintenance of the large volume (+300 cc) fat grafts.
=== Prenatal and newborn screening === Checking for sickle cell disease begins during pregnancy, with a prenatal screening questionnaire that includes, among other things, a consideration of health issues in the child's parents and close relatives. During pregnancy, genetic testing can be done on either a blood sample from the foetus or a sample of amniotic fluid. During the first trimester of pregnancy, chorionic villus sampling (CVS) is a technique used for prenatal diagnosis of sickle cell disease. A routine heel prick test, in which a small sample of blood is collected a few days after birth, is used to check conclusively for sickle cell disease as well as other inherited conditions.
Hayes (1904), pioneering cultural historian; former U.S. ambassador to Spain Edward Sapir (1904), linguist and co-creator of the Sapir–Whorf hypothesis Frank Speck (1904), anthropologist, professor at the University of Pennsylvania William Stuart Messer (1905), professor of Latin at Dartmouth College, recipient of a 1922 Rome Prize Mark Raymond Harrington (1907), curator at the Southwest Museum of the American Indian and owner of the Rómulo Pico Adobe Edwin Borchard (1908), international legal scholar; Sterling Professor at the Yale Law School Richard F. Bach (1909), curator with the Metropolitan Museum of Art Rhys Carpenter (1909), classical art historian and professor at Bryn Mawr College F. Stuart Chapin (1909), sociologist and former president of the American Sociological Association Harold Gould Henderson (1910), Japanologist and former president of the Japan Society, founder of the Haiku Society of America Armin K. Lobeck (1911), cartographer Carl Zigrosser (1911), curator of the Philadelphia Museum of Art Lawrence K. Frank (1912), social scientist; vice president of the Josiah Macy Jr.
(5.2.1) A sponsor may transfer any or all of the sponsor's trial-related duties and functions to a CRO, but the ultimate responsibility for the quality and integrity of the trial data always resides with the sponsor. The CRO should implement quality assurance and quality control. (5.2.2) Any trial-related duty and function that is transferred to and assumed by a CRO should be specified in writing. The sponsor should ensure oversight of any trial-related duties and functions carried out on its behalf, including trial-related duties and functions that are subcontracted to another party by the sponsor's contracted CRO(s). (5.2.3) Any trial-related duties and functions not specifically transferred to and assumed by a CRO are retained by the sponsor. (5.2.4) All references to a sponsor in this guideline also apply to a CRO to the extent that a CRO has assumed the trial-related duties and functions of a sponsor. Guidance from the US FDA published in 2013 also speaks to the responsibility of the sponsor to oversee work of the CRO, including the circumstance where risk-based monitoring has been delegated to the CRO. 2021 saw a major update to US FDA regulations related to providing the agency with information about CROs and how they "comply with FDA regulations".
=== Biological fluorescence === Chemical biologists often study the functions of biological macromolecules using fluorescence techniques. The advantage of fluorescence versus other techniques resides in its high sensitivity, non-invasiveness, safe detection, and ability to modulate the fluorescence signal. In recent years, the discovery of green fluorescent protein (GFP) by Roger Y. Tsien and others, hybrid systems and quantum dots have enabled assessing protein location and function more precisely. Three main types of fluorophores are used: small organic dyes, green fluorescent proteins, and quantum dots. Small organic dyes usually are less than 1 kDa, and have been modified to increase photostability and brightness, and reduce self-quenching. Quantum dots have very sharp wavelengths, high molar absorptivity and quantum yield. Both organic dyes and quantum dyes do not have the ability to recognize the protein of interest without the aid of antibodies, hence they must use immunolabeling. Fluorescent proteins are genetically encoded and can be fused to your protein of interest. Another genetic tagging technique is the tetracysteine biarsenical system, which requires modification of the targeted sequence that includes four cysteines, which binds membrane-permeable biarsenical molecules, the green and the red dyes "FlAsH" and "ReAsH", with picomolar affinity. Both fluorescent proteins and biarsenical tetracysteine can be expressed in live cells, but present major limitations in ectopic expression and might cause a loss of function.
Sources: en.wikipedia.org
A trackway consisting of four footprints discovered near Marmarth, North Dakota in 2025 and described in 2026 have been attributed to an adult Tyrannosaurus based on the shape and size of the tracks, which measure 1 m (3.3 ft). The set of tracks suggests a stride length of 4 m (13 ft) for the animal that made them, with speed estimates of 1.5–2 meters per second (3.4-4.5 mph). The fluvial environment of the upper Hell Creek Formation, from which the footprints were unearthed may explain the significant scarcity of trackways and the uncommon nature of theropod footprints in the formation in general. Three of the footprints are expected to be recovered in autumn of 2026 to be displayed at the Denver Museum of Nature and Science.
"Osteogenesis Imperfecta Overview". NIH Osteoporosis and Related Bone Diseases. National Resource Center, National Institutes of Health, U.S. Department of Health and Human Services. 8 May 2023. Archived from the original on 4 October 2017.
==== Properties ==== The significant disadvantages of hide glue—its thermal limitations, short open time, and vulnerability to micro-organisms—are offset by several advantages. Hide glue joints are reversible and repairable. Recently glued joints will release easily with the application of heat and steam. Hide glue sticks to itself, so the repairer can apply new hide glue to the joint and reclamp it. In contrast, PVA glues do not adhere to themselves once they are cured, so a successful repair requires removal of the old glue first—which usually requires removing some of the material being glued. Hide glue creates a somewhat brittle joint, so a strong shock will often cause a very clean break along the joint. In contrast, cleaving a joint glued with PVA will usually damage the surrounding material, creating an irregular break that is more difficult to repair. This brittleness is taken advantage of by instrument makers. For example, instruments in the violin family require periodic disassembly for repairs and maintenance. The top of a violin is easily removed by prying a palette knife between the top and ribs, and running it all around the joint. The brittleness allows the top to be removed, often without significant damage to the wood. Regluing the top only requires applying new hot hide glue to the joint. If the violin top were glued on with PVA glue, removing the top would require heat and steam to disassemble the joint (causing damage to the varnish), then wood would have to be removed from the joint to ensure no cured PVA glue was remaining before regluing the top.
=== Screenwriter === Culp wrote scripts for seven I Spy episodes, one of which he also directed. He later wrote and directed two episodes of The Greatest American Hero, including the series finale. Culp also wrote scripts for other television series, including Trackdown, a two-part episode from The Rifleman, and Cain's Hundred.
Sources: en.wikipedia.org
==== Second Sino-Japanese War ==== Liu played on patriotic sentiment during the War of Resistance against Japan. In 1937, he attended a meeting of the Ya'an Anti-Japanese National Salvation Association, admitting his past "mistakes" in fighting other Chinese. He also donated a sum of 500,000 yuan to the war effort. However, while other Sichuan warlords such as Liu Xiang, Yang Sen, Li Jiayu, and Wang Mingzhang sent troops to fight the Japanese, Liu Wenhui refrained from doing the same, citing the need to defend the Tibetan frontier and a lack of equipment. Therefore, Liu Wenhui's 24th Army did not directly participate in the war. Instead, Liu's policy was that of "resisting Japan by building Xikang." According to the state-run New Xikang Post (新康報), the province complied with the wartime orders of the central government regarding resource and population mobilization. After the flight of the Nationalist government to Chongqing, Chiang became interested in establishing a presence in Xikang, proposing in either late 1938 or early 1939 to establish the "Xichang Headquarters" if ever Chongqing were to fall. To prepare for this task, he appointed Zhang Dulun, another of Liu's Baoding classmates, to lead the headquarters and moved the 36th (German-trained) division to Xichang. A power struggle developed in Xichang between Zhang and Liu, with Zhang attempting various measures to undermine Liu's control over Xichang.
=== Research === During his long career at WSLH, Inhorn pursued many different lines of medical research and public health intervention. In 1960, WSLH was involved in a large community program to promote the new Pap smear test for detecting the early stages of cervical cancer. Inhorn devoted many hours to training personnel in family planning clinics on how to carefully make and screen the Pap smear, both of which are essential to its success. During this time, Inhorn also became active in the American Society of Cytopathology. He chaired its committees to develop best practices in laboratory operation, and he eventually became president of ASC, later receiving the Papanicolaou Award for his contributions to the field of cytopathology. In addition, by 1960, new techniques in the field of cytogenetics permitted the study of infants and children with congenital malformations. Inhorn provided the laboratory component that permitted pediatricians from the UW Medical Center to study a large number of affected children. In particular, Down syndrome had been identified as having three chromosome 21s, instead of two. The Cytogenetics Lab at WSLH identified another trisomy (trisomy 13), an important discovery contributing to the genomic revolution that followed.
=== RNaseA === In 1959, Fred Richards discovered that a proteolytic enzyme, Subtilisin, had the ability to cleave the enzyme Ribonuclease A into two components, a peptide corresponding to the first 20 amino acids of the enzyme (S-Peptide) and the remainder of the protein (S-Protein). When separated from one another, each piece was inactive but when they were simply mixed together, full enzymatic activity was restored. Hofmann speculated that this system might be a model for the way peptide hormones interact with their receptors. Structure-function studies with ACTH were complicated by the necessity to assess activity in the whole animal. The S-Peptide:S-Protein system afforded a simple system with none of the biological complications inherent in testing ACTH analogs. To study which amino acids might be important in establishing the binding between peptide hormones and their receptors, Hofmann and his group began a systematic evaluation of the contributions each amino acid in the S-Peptide molecule made to the binding with S-Protein. The ability of synthetic analogs of S-Peptide to activate S-Protein correlated well with those of synthetic ACTH analogs to elicit hormonal activity: 1) only a portion of the S-Peptide chain was essential for re-establishing full activity with the S-Protein; 2) methionine was not important; 3) substituting one particular amino acid in the peptide not only destroyed the activity of the peptide but created an antagonist as well.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.